Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network
In: Blood, Jg. 140 (2022-11-15), Heft Supplement 1, S. 1-3
Online
academicJournal
Zugriff:
Titel: |
Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network
|
---|---|
Autor/in / Beteiligte Person: | Dreyling, Martin ; Doorduijn, Jeanette K. ; Gine, Eva ; Jerkeman, Mats ; Walewski, Jan ; Hutchings, Martin ; Mey, Ulrich ; Riise, Jon ; Trneny, Marek ; Vergote, Vibeke K.J. ; Celli, Melania ; Shpilberg, Ofer ; Gomes da Silva, Maria ; Leppa, Sirpa ; Jiang, Linmiao ; Pott, Christiane ; Klapper, Wolfram ; Gözel, Döndü ; Schmidt, Christian ; Unterhalt, Michael ; Ladetto, Marco ; Hoster, Eva |
Link: | |
Zeitschrift: | Blood, Jg. 140 (2022-11-15), Heft Supplement 1, S. 1-3 |
Veröffentlichung: | 2022 |
Medientyp: | academicJournal |
ISSN: | 0006-4971 (electronic) |
DOI: | 10.1182/blood-2022-163018 |
Sonstiges: |
|